本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、召开时间：2025 年 6 月 12 日（星期四）14:00-16:40 2、召开地点：全景路演（https://rs.p5w.net）网络平台 3、召开方式：网络文字互动 一、活动安排 证券代码：002932 证券简称：明德生物 公告编号：2025-034 武汉明德生物科技股份有限公司 关于参加 2025 年湖北辖区上市公司投资者网上集体接待日活动 暨 2024 年度业绩说明会的公告 为进一步加强武汉明德生物科技股份有限公司（以下简称"公司"）与投资 者互动交流，公司将于 2025 年 6 月 12 日参加由湖北证监局、湖北省上市公司协 会与深圳市全景网络有限公司联合举办的 2025 年湖北辖区上市公司投资者网上 集体接待日活动，届时将通过网络文字互动方式与广大投资者就公司 2024 年度 业绩、发展战略、经营状况、公司治理等投资者关注的问题进行交流与沟通。 二、召开的时间、地点及方式 召开时间：2025 年 6 月 12 日（星期四）14:00-16:40 召开地点：全景路演（https:// ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Mingde Biological, which closed at 21.46 yuan, up 9.99%, with a rolling PE ratio of 128.59, marking a new low in 280 days, and a total market capitalization of 4.99 billion yuan [1][2] - The average PE ratio for the medical device industry is 50.97, with a median of 36.67, positioning Mingde Biological at the 109th rank within the industry [1][2] - As of the first quarter of 2025, six institutions hold shares in Mingde Biological, including four funds and two insurance companies, with a total holding of 13.84 million shares valued at 250 million yuan [1] Group 2 - Mingde Biological specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, with key products including in vitro diagnostic reagents, critical care information solutions, and third-party medical testing services [1] - The latest financial results for the first quarter of 2025 show that the company achieved a revenue of 69.96 million yuan, a year-on-year increase of 14.76%, while net profit was -3.66 million yuan, a year-on-year decrease of 111.43%, with a gross profit margin of 16.37% [1]

Core Viewpoint - The company has announced its 2024 annual profit distribution plan, which includes a cash dividend of 12.00 RMB per 10 shares (tax included) for all shareholders, with adjustments based on the number of shares held in the company's repurchase account [2][4]. Summary by Sections 1. Profit Distribution Plan - The profit distribution plan was approved at the shareholders' meeting on May 16, 2025, and will distribute cash dividends without issuing bonus shares or capitalizing reserves [2]. - The total share capital for the distribution is 232,520,957 shares, excluding 13,034,741 shares held in the repurchase account, resulting in a base of 219,486,216 shares for the cash dividend calculation [2][4]. 2. Cash Dividend Details - Each shareholder will receive a cash dividend of 12.00 RMB per 10 shares (tax included), with different tax treatments for various types of shareholders [2][4]. - The total cash dividend amount is calculated as 263,383,459.20 RMB, based on the participating share capital multiplied by the distribution ratio [4]. 3. Ex-Dividend Date and Record Date - The record date for the distribution is set for June 11, 2025, and the ex-dividend date is June 12, 2025 [3]. 4. Distribution Method - Cash dividends will be directly credited to shareholders' accounts through their securities companies or other custodians [3]. 5. Adjustments and Calculations - The ex-dividend price will be adjusted based on the cash dividend amount, calculated as 1.1327299 RMB per share, which will be deducted from the closing price on the record date [4].

Core Viewpoint - The company has approved the use of idle raised funds for cash management, allowing investment in low-risk financial products up to 230 million yuan, aiming to enhance fund utilization efficiency and increase returns for the company and its shareholders [1][4]. Group 1: Investment Management - The company will use no more than 230 million yuan of idle raised funds for investments in safe, liquid, and principal-protected financial products or time deposits, with the funds being available for rolling use within 12 months from the shareholder meeting approval [1]. - A dedicated settlement account for the raised funds has been established, ensuring that these funds will only be used for cash management and will not be mixed with non-raised funds [3]. Group 2: Risk Control Measures - The company will adhere to prudent investment principles, selecting reputable financial institutions with strong risk control measures for cash management [2]. - The company will conduct timely analysis and monitoring of the financial products' performance, taking necessary actions if risks to fund safety are identified [2]. - The audit department will oversee the use and custody of funds related to this cash management initiative, ensuring compliance and risk evaluation [2]. Group 3: Impact on Operations - The establishment of the dedicated settlement account and the planned cash management will not alter the intended use of raised funds, ensuring that daily operations and investment projects remain unaffected [2]. - The company emphasizes that this strategy is aimed at safeguarding the required funds for investment projects while enhancing the overall safety and efficiency of fund usage [2].

证券代码：002932 证券简称：明德生物 公告编号：2025-033 武汉明德生物科技股份有限公司 关于开立募集资金现金管理产品专用结算账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 武汉明德生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日 召开第四届董事会第十九次会议、第四届监事会第十六次会议，2025 年 5 月 16 日召开 2024 年年度股东大会审议通过了《关于使用部分闲置募集资金进行现金 管理的议案》，同意公司使用不超过 23,000.00 万元（含）的闲置募集资金投资 安全性高、流动性好、保本型的理财产品或定期存款、结构性存款，在上述额度 内，资金可在公司股东大会审议通过之日起 12 个月内滚动使用。董事会授权总 经理行使该项投资决策权并由财务负责人负责具体购买事宜。具体内容详见公司 于 2025 年 4 月 25 日在巨潮资讯网披露的《关于使用部分闲置募集资金进行现金 管理的公告》（公告编号：2025-021）。 集资金进行现金管理购买理财产品的结算，不会用于存放非募集资金或用作其他 用途。 二、投资风险 ...

证券代码：002932 证券简称：明德生物 公告编号：2025-032 武汉明德生物科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、武汉明德生物科技股份有限公司（以下简称"公司"）本次实施的利润 分配方案按公司现有总股本 232,520,957 减去公司回购专户中持有的股份数量 13,034,741 股为基数，向全体股东每 10 股派发现金红利 12.00 元（含税），不送 红股，不以公积金转增股本。 2、因公司回购股份不参与分红，本次权益分派实施后，根据股票市值不变 原则，实施权益分派前后公司总股本保持不变，现金分红总额分摊到每一股的比 例将减少。因此，本次权益分派实施后除权除息价格计算时，每股现金红利（含 税）应以1.1327299元/股计算（每股现金红利=现金分红总额/总股本，即1.1327299 元/股=263,383,459.20 元÷232,520,957 股）（结果取小数点后七位，最后一位直 接截取，不四舍五入），按公司总股本（含回购股份）折算每 10 股现金分红金 额（含税）为 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Mingde Biological Technology Co., Ltd., particularly its stock performance and industry comparison [1][2] - As of June 3, the closing price of Mingde Biological was 19.71 yuan, with a PE ratio of 118.10, marking a new low in 111 days, and a total market capitalization of 4.583 billion yuan [1] - The average PE ratio for the medical device industry is 50.80, with a median of 36.71, positioning Mingde Biological at the 108th rank within the industry [1][2] Group 2 - As of April 18, 2025, the number of shareholders for Mingde Biological was 25,248, a decrease of 345 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of the company includes the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as solutions for critical care information and third-party medical testing services [1] - In the latest quarterly report for Q1 2025, the company reported a revenue of 69.96 million yuan, a year-on-year increase of 14.76%, but a net loss of approximately 3.66 million yuan, representing a year-on-year decline of 111.43%, with a gross profit margin of 16.37% [1]

证券代码：002932 证券简称：明德生物 公告编号：2025-031 武汉明德生物科技股份有限公司 对外投资进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、进展情况说明 基于发展战略调整，经全体合伙人协商一致，全体合伙人同比例减少认缴出 资额。近日公司收到青柠基金完成工商变更登记通知，认缴出资额由 12,000 万 元人民币变更为 9,960 万元人民币，其中，公司认缴出资额由 2,450 万元人民币 减少为 2,033.50 万元人民币。合伙人认缴出资变更情况如下： | 合伙人名称 | 变更前认缴出 | 变更前出资 | 变更后认缴出 | 变更后出 | | --- | --- | --- | --- | --- | | | 资额（万元） | 比例 | 资额（万元） | 资比例 | | 武汉明德生物科技股份有限公司 | 2,450 | 20.42% | 2,033.50 | 20.42% | | 湖北长创产业投资基金有限公司 | 2,450 | 20.42% | 2,033.50 | 20.42% | | --- | --- | --- | -- ...

Company Overview - Mingde Biological Technology Co., Ltd. specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as information solutions for critical care and third-party medical testing services [1] - The company's main products include in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] Financial Performance - As of the first quarter of 2025, the company reported revenue of 69.96 million yuan, representing a year-on-year increase of 14.76% [1] - The net profit for the same period was -3.66 million yuan, showing a year-on-year decline of 111.43% [1] - The gross profit margin for the company was 16.37% [1] Market Position - The company's current stock price is 18.75 yuan, with a decline of 1.16% [1] - The rolling price-to-earnings (PE) ratio is 112.35, significantly higher than the industry average of 48.92 and the industry median of 35.68, placing the company at the 108th position in the industry ranking [1][2] - The total market capitalization of the company is 4.36 billion yuan [1] Institutional Holdings - As of the first quarter of 2025, six institutions hold shares in Mingde Biological, including four funds and two insurance companies, with a total holding of 13.84 million shares valued at 250 million yuan [1]

Group 1 - The core viewpoint of the articles indicates that Mingde Biological's stock is currently underperforming with a closing price of 19.0 yuan, down 1.91%, and a rolling PE ratio of 113.85 times, significantly higher than the industry average [1][2] - The total market capitalization of Mingde Biological is reported at 4.418 billion yuan, ranking 108th in the medical device industry based on PE ratio [1][2] - The company experienced a net outflow of 4.511 million yuan in major funds on May 22, with a total outflow of 11.4719 million yuan over the past five days, indicating a negative trend in investor sentiment [1] Group 2 - Mingde Biological specializes in the research, production, sales, and service of in vitro diagnostic reagents and instruments, as well as providing information solutions for critical care and third-party medical testing services [1] - The latest financial report for Q1 2025 shows that the company achieved operating revenue of 69.9603 million yuan, a year-on-year increase of 14.76%, but reported a net loss of approximately 3.662988 million yuan, a year-on-year decline of 111.43%, with a gross profit margin of 16.37% [1]